文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

首次异基因移植后复发患者接受单倍体相合移植

Haploidentical transplants for patients with relapse after the first allograft.
PubMed 文献 · Am J Hematol · 2020-08-01

该研究分析了本机构29例首次异基因造血干细胞移植后复发的血液恶性肿瘤患者,接受单倍体相合移植作为二次移植。中位随访46.9个月,3年复发率30%、非复发死亡率39%、无进展生存率31%、总生存率40%。多变量分析显示HCT-CI和供者特异性抗HLA抗体与更差结局显著相关;HCT-CI<3且无DSA者3年PFS和OS分别为53%和60.3%。作者认为单倍体相合移植作为二次异基因移植可行且可能治愈。

要点

  • 首次异基因移植后复发患者接受单倍体相合二次移植,3年OS为40%、PFS为31%。
  • HCT-CI<3且无DSA者3年PFS为53%、OS为60.3%。
  • HCT-CI和DSA与二次移植后更差结局显著相关。

核心结论

  • 作者认为单倍体相合移植作为二次异基因造血干细胞移植可行且可能治愈。
  • 较低的HCT-CI和无DSA与更低的非复发死亡率和更好的生存相关。
  • 单倍体相合移植物可能是二次异基因移植的首选供者来源,因为这些高危患者常需紧急移植。

研究设计与样本

  • 单中心分析2009年2月至2018年10月在本机构连续接受单倍体相合移植作为二次移植的首次异基因移植后复发的血液恶性肿瘤患者(N=29)。
  • 中位年龄36岁(四分位距24-60);83%患者疾病风险指数为高/极高;61%的AML/MDS患者具有高危细胞遗传学;仅24%在移植时处于完全缓解。

主要发现

  • 中位随访46.9个月,3年复发率30%、非复发死亡率39%、无进展生存率31%、总生存率40%。
  • 多变量分析中,HCT-CI和二次移植前可检测到的供者特异性抗HLA抗体(DSA)与更差结局显著相关。
  • HCT-CI<3且无DSA的患者3年无进展生存率和总生存率分别为53%和60.3%。

关键数值与推荐

  • 3年复发率30%、非复发死亡率39%、无进展生存率31%、总生存率40%(N=29,中位随访46.9个月)。
  • HCT-CI<3且无DSA者3年无进展生存率53%、总生存率60.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse after allogeneic hematopoietic stem-cell transplantation (AHSCT) is associated with very poor outcomes. A second transplant offers the possibility of long-term disease control. We analyzed outcomes with haploidentical donors for second allograft at our institution. All consecutive patients with hematological malignancies (N = 29) who relapsed after AHSCT and underwent a haploidentical transplant (haploSCT) as second transplant between February 2009 and October 2018 were included. Median age was 36 years (interquartile range (IQR) 24-60); 83% of patients had high/very high disease risk index; 61% of AML/MDS patients had high-risk cytogenetics; and only 24% were in complete remission at transplant. With a median follow-up of 46.9 months, the 3-year relapse, non-relapse mortality (NRM), progression-free survival (PFS) and overall survival (OS) were 30%, 39%, 31% and 40%, respectively. In multivariable analysis (MVA), comorbidity index (HCT-CI) and detectable donor-specific anti-HLA antibodies (DSA) prior to second transplant were significantly associated with worse outcomes. Patients with HCT-CI <3 and without DSA had 3-year PFS and OS of 53% and 60.3%, respectively. Our findings suggest that haploSCT as second AHSCT is feasible and potentially curative. Lower HCT-CI and no DSA were associated with lower NRM and improved survival. Haploidentical grafts might be a preferred donor source for second AHSCT as these are high-risk patients who frequently need to proceed urgently to transplant.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Srour SA, Kongtim P, Rondon G, et al. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. 2020. PMID: 32619033. doi:10.1002/ajh.25924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。